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itamin D has important roles in physiological processes and is primarily involved in calcium and phosphorus homeostasis and musculoskeletal system metabolism (1, 2) . Moreover, vitamin D acts on the cardiovascular system and in systemic inflammation, oxidative stress, and immune regulation (1, 2) . Vitamin D deficiency has been proposed as a risk factor for many diseases that are not traditionally associated with vitamin D and mineral metabolism, such as cancer, cardiovascular disease, hypertension, and diabetes (1, 2) . In addition, studies have shown an inverse association between vitamin D and visceral adiposity (3) .
Q fever is a worldwide zoonosis caused by Coxiella burnetii (4). Endocarditis is the most-serious complication of Q fever, and the optimal duration of treatment using doxycycline and hydroxychloroquine is 18 months for native valves and 24 months for prosthetic valves (5, 6) . However, patients treated with doxycycline and hydroxychloroquine are not exposed to sunlight because they commonly present photosensitivity, including sunburn, photosensitive eruptions, blistering, rash, pruritus, and photoonycholysis (7, 8) . Our study was based on the experience of a medical doctor who was treated for 1 year with doxycycline and hydroxychloroquine and who notified one of us (D.R.) that he had found that he had a low level of vitamin D. The aim of this study was to investigate the levels of vitamin D in patients with treated Q fever endocarditis. We retrospectively compared the vitamin D levels of patients who were receiving doxycycline and hydroxychloroquine and a control group without antibiotic therapy.
This study was performed after ethical approval by the local ethics committee (accession number 10-002, 2010). Sera were obtained from the outpatients of an infectious disease unit (Hopital La Timone, Marseille, France) who were suffering from Q fever and treated with doxycycline (100 mg twice per day) and hydroxychloroquine (200 mg three times per day). Doses were adjusted monthly based on drug monitoring (0.8 to 1.2 mg/ml for hydroxychloroquine and Ͼ4.8 mg/ml for doxycycline) (5). Healthy individuals without antibiotic treatment for at least 6 months (Hopital La Timone, Marseille, France) were used as controls. The exclusion criteria were an age under 18 years, a history of cancer, inflammatory bowel disease or acute or chronic diarrhea in the previous 4 weeks, vitamin D administration, and the administration of another antibiotic Ͼ6 months before sampling. Total vitamin D (25-OH vitamin D2 and 25-OH vitamin D3) concentrations were determined for each patient using the Liaison (DiaSorin, Stillwater, MN) automated competitive immunoassay. Three groups were identified, as follows: group I, doxycycline-hydroxychloroquine treatment for more than 3 months; group II, doxycycline-hydroxychloroquine treatment for less than 3 months; and group III, control (no antibiotic treatment). Vitamin D levels were calculated for all of the patients. For data comparison, we used EpiInfo version 6.0 (Centers for Disease Control and Prevention, Atlanta, GA, USA). A P value of Ͻ0.05 was considered significant.
Overall, we tested 106 patients, including 56 with Q fever endocarditis and 50 controls ( Table 1 ). The median age Ϯ interquartile range (IR) was 54 Ϯ 15 years, and 57 (63%) were males. All patients with Q fever endocarditis were treated with doxycycline and hydroxychloroquine. Forty patients had been receiving treatment for less than 3 months at the time of sampling, and 16 patients had been receiving treatment for more than 3 months at the time of sampling. The vitamin D levels were significantly higher in the control group than in Q fever patients treated with doxycycline and hydroxychloroquine (P Ͻ 0.0001) (Fig. 1a) . The duration of treatment was also associated with the level of vitamin D (P Ͻ 0.0001), and control patients presented significantly higher vitamin D levels than patients receiving doxycycline-hydroxychloroquine, whether for less than or for more than 3 months (P Ͻ 0.0001 and P Ͻ 0.0001, respectively) (Fig. 1b) . Lastly, patients receiving treatment for more than 3 months presented significantly lower vitamin D levels than patients treated for less than 3 months (P ϭ 0.01).
Our study demonstrates that doxycycline-hydroxychloroquine administration was associated with a significant reduction in vitamin D levels and that the duration of treatment also affected vitamin D levels. Low vitamin D levels have been associated with increased activation of the renin-angiotensin system, leading to elevated blood pressure and associated with increased cardiovascular disease (9) . Meta-analysis results showed that higher levels of vitamin D among middle-aged and elderly populations were associated with a decrease in cardiovascular disease, type 2 diabetes, and metabolic syndrome (10) . Recently, vitamin D deficiency was found to be a potential risk factor for obesity and the development of insulin resistance, leading to type 2 diabetes (11) . Low vitamin D levels may contribute to obesity or inhibit weight loss (12), although randomized controlled trials testing the effect of vitamin D supplementation on weight have provided inconsistent findings (9, 13). However, it was proposed that the vitamin D pathway genes are unlikely to play a major role in obesity-related traits in the general population (14) .
In conclusion, we found in patients an association of vitamin D deficiency with long-term doxycycline-hydroxychloroquine treatment. The causation of this deficiency cannot be concluded from this work. Vitamin D is primarily produced in the skin by the action of sunlight (2), and possibly patients receiving doxycyclinehydroxychloroquine treatment are not exposed to sunlight because of photosensitization and thus present vitamin D deficiency. We propose that patients with long-term doxycycline-and-hydroxychloroquine treatment should be regularly tested, and in cases of vitamin D deficiency, treatment with a vitamin D supplement should be added.
